2M.D. Associate Professor, Ankara Training and Research Hospital, Eye Clinic, Ankara/TURKEY Purpose: To evaluate the rate of posterior vitreous detachment (PVD) development in patients who recieved intravitreal injections for age-related macular degeneration (AMD) and to compare the visual and anatomical results with the patients not developed PVD.
Materials and Methods: Medical records of patients who recieved intravitreal anti vascular endothelial growth factor (anti-VEGF) treatment for AMD were evaluated retrospectively. According to the fundoscopic examination, .ultrasonography (USG) and optical coherence tomography (OCT) records patients without PVD were included to the study. The rate of PVD development was detected. The visual acuity (VA) and central foveal thickness (CFT) initially, at 3rd,6th,9th,12th months and at final visit were evaluated.
Results: The mean age of 35 patients was 69.6±8.9 years. Five cases (%14.3) developed PVD during the follow up. The median (minimum-maximum) VA of the patients without PVD (PVD-) at 3rd,6th,9th,12th month and at last visit was 57.5 (15-85), 61.5 (16-88), 55 (3-88), 42 (1-87), 42.5 (7-85), 34 (1-83) letters respectively. Visual acuity of the patients who developed PVD (PVD+) was 57 (44-69), 72 (66-77), 68 (57-77), 70 (50-75), 65 (55-78) and 52 (20-70) letters respectively. The CFT (minimum-maximum) in the PVD- group was 300 (149-589), 198 (128-484), 219.5 (100-555), 246 (145-513), 217 (146-606), 241 (128-517) μm, in the PVD+ group it was 252 (187-814), 156 (115-520), 173 (135-287), 219 (144-225), 225 (191-332), 231 (94-296) μm respectively. Posterior vitreous detachment developed after a median (minimum-maximum) of 6 (3-9) injections.
Conclusion: Development of PVD can effect positively the anatomical and visual prognosis during AMD treatment.
Keywords : Age related macular degeneration, ranibizumab, posterior vitreous detachment